



## TABLE OF CONTENTS

|                                                                          |    |
|--------------------------------------------------------------------------|----|
| 1. INTRODUCTION .....                                                    | 1  |
| 2. LITERATURE REVIEW.....                                                | 7  |
| 2.1 DRUG RESISTANCE ASSOCIATED WITH CANCER CHEMOTHERAPY.....             | 7  |
| 2.2 MULTIDRUG RESISTANCE .....                                           | 8  |
| 2.2.1 P-glycoprotein.....                                                | 8  |
| 2.3 STRATEGIES USED TO OVERCOME MDR OF CANCER CELLS.....                 | 11 |
| 2.3.1 Non-substrate strategy.....                                        | 12 |
| 2.3.2 Development of cytostatics that have a fast cellular uptake .....  | 13 |
| 2.3.3 Interfering with ATP hydrolysis .....                              | 13 |
| 2.3.4 Altering integrity of membrane lipids .....                        | 13 |
| 2.3.5 Use of Pgp modulators .....                                        | 14 |
| 2.3.6 Controlling the expression of MDR proteins .....                   | 14 |
| 2.3.7 Novel drug delivery systems in circumventing Pgp mediated MDR..... | 16 |
| 2.4 DRUG TARGETING .....                                                 | 20 |
| 2.5 ENHANCED PERMEATION AND RETENTION EFFECT .....                       | 21 |
| 2.6 DRUG PROFILE .....                                                   | 22 |
| References.....                                                          | 27 |
| 3. ANALYTICAL METHODS .....                                              | 33 |
| 3.1 IDENTIFICATION OF PACLITAXEL BY FTIR.....                            | 33 |
| 3.2 ESTIMATION OF PTX.....                                               | 33 |
| 3.2.1 UV-VISIBLE SPECTROSCOPY .....                                      | 33 |
| 3.2.2 High Performance Liquid Chromatography.....                        | 39 |
| 3.2.3 Estimation of PTX in rat plasma and tissue homogenates .....       | 40 |
| 3.3 ESTIMATION OF 6-COUMARIN .....                                       | 48 |
| 3.3.1 Estimation of 6-coumarin in formulations .....                     | 48 |
| 3.3.2 Estimation of 6-coumarin in cell lysate .....                      | 50 |
| 3.4 ESTIMATION OF RESIDUAL PVA.....                                      | 51 |
| 3.5 DETERMINATION OF PROTEIN (TRANSFERRIN) BY BCA METHOD.....            | 52 |
| References.....                                                          | 54 |
| 4. FORMULATION DEVELOPMENT, CHARACTERIZATION AND STABILITY STUDIES.....  | 55 |
| 4.1 INTRODUCTION.....                                                    | 55 |
| 4.2 MATERIALS.....                                                       | 59 |
| 4.3 METHODS .....                                                        | 59 |

|                                                                                                            |    |
|------------------------------------------------------------------------------------------------------------|----|
| 4.3.1 PTX LOADED PLGA NPS .....                                                                            | 59 |
| 4.3.1.1 Preparation and optimization of PTX loaded PLGA NPs .....                                          | 59 |
| 4.3.1.2 Surface modification by coating with Pluronic®P85 .....                                            | 70 |
| 4.3.1.3 Surface modification by conjugation with Transferrin .....                                         | 70 |
| 4.3.1.4 Preparation of coumarin-6 loaded PLGA NPs, Pluronic®P85 coated and Tf<br>conjugated PLGA NPs ..... | 72 |
| 4.3.1.5 Estimation of residual PVA.....                                                                    | 72 |
| 4.3.1.6 Entrapment efficiency and in-vitro drug release.....                                               | 72 |
| 4.3.1.7 Particle size and zeta potential.....                                                              | 73 |
| 4.3.1.8 Effect of different cryoprotectants added during freeze drying on stability<br>of NPs .....        | 73 |
| 4.3.1.9 Differential Scanning calorimetry .....                                                            | 73 |
| 4.3.1.10 NMR spectroscopy.....                                                                             | 74 |
| 4.3.1.11Transmission electron microscopy .....                                                             | 74 |
| 4.3.2 PTX LOADED POLY(N-BUTYL CYANOACRYLATE) NPS .....                                                     | 74 |
| 4.3.2.1 Preparation of PTX loaded poly(n-butylcyano acrylate) NPs.....                                     | 74 |
| 4.3.2.2 6-coumarin loaded PBCA NPs .....                                                                   | 75 |
| 4.3.2.3 Turbidimetric studies to monitor particle formation .....                                          | 75 |
| 4.3.2.4 Entrapment efficiency and In-vitro drug release.....                                               | 75 |
| 4.3.2.5 Particle size and zeta potential analysis .....                                                    | 76 |
| 4.3.2.6 Effect of different cryoprotectants added during freeze drying on stability<br>of NPs .....        | 76 |
| 4.3.2.7 FTIR studies .....                                                                                 | 76 |
| 4.3.2.8 Differential scanning calorimetry studies .....                                                    | 76 |
| 4.3.2.9 Molecular weight determination.....                                                                | 77 |
| 4.3.2.10 NMR spectroscopy.....                                                                             | 77 |
| 4.3.2.11 Transmission electron microscopy .....                                                            | 77 |
| 4.3.3 PTX LOADED GLYCERYL TRISTEARATE SLN .....                                                            | 77 |
| 4.3.3.1 Partitioning of PTX between lipids and distilled water.....                                        | 77 |
| 4.3.3.2 Preparation of PTX loaded Glyceryl tristearate SLN .....                                           | 78 |
| 4.3.3.3 Preparation of coumarin-6 loaded GTS SLN .....                                                     | 87 |
| 4.3.3.4 Entrapment efficiency and in-vitro drug release.....                                               | 87 |
| 4.3.3.5 Particle size and zeta potential.....                                                              | 88 |
| 4.3.3.6 Effect of different cryoprotectants added during freeze drying on stability<br>of NPs .....        | 88 |
| 4.3.3.7 Differential Scanning calorimetry .....                                                            | 88 |
| 4.3.3.8 X ray diffraction studies .....                                                                    | 88 |

|                                                                                                      |     |
|------------------------------------------------------------------------------------------------------|-----|
| 4.3.3.9 Transmission electron microscopy .....                                                       | 88  |
| 4.3.3.10 Determination of in-vitro steric stability by electrolyte induced<br>floculation test ..... | 89  |
| 4.3.4 STABILITY STUDIES .....                                                                        | 89  |
| 4.3.4.1 Stability testing protocol .....                                                             | 90  |
| 4.4 RESULTS AND DISCUSSION .....                                                                     | 90  |
| 4.4.1 PTX LOADED PLGA NPS .....                                                                      | 90  |
| 4.4.1.1 Preparation and optimization of PTX loaded PLGA NPs .....                                    | 90  |
| 4.4.1.2 Surface modification by coating with Pluronic®P85 .....                                      | 96  |
| 4.4.1.3 Surface modification by conjugation with Transferrin .....                                   | 96  |
| 4.4.1.4 Estimation of residual PVA .....                                                             | 98  |
| 4.4.1.5 Characterization of PTX loaded NPs .....                                                     | 99  |
| 4.4.1.6 Coumarin-6 loaded PLGA NPs .....                                                             | 100 |
| 4.4.1.7 Effect of different cryoprotectants added during freeze drying on stability<br>of NPs .....  | 100 |
| 4.4.1.8 In-vitro drug release .....                                                                  | 103 |
| 4.4.1.9 Differential scanning calorimetry .....                                                      | 104 |
| 4.4.1.10 Transmission electron microscopy .....                                                      | 104 |
| 4.4.2 PTX LOADED POLY(N-BUTYL CYANOACRYLATE) NPS .....                                               | 106 |
| 4.4.2.1 Preparation and optimization of PTX loaded PBCA NPs .....                                    | 106 |
| 4.4.2.2 Effect of different formulation and process variables on PS, EE and Zeta<br>potential .....  | 109 |
| 4.4.2.3 Turbidimetric measurements for particle formation .....                                      | 120 |
| 4.4.2.4 Effect of different cryoprotectants added during freeze drying .....                         | 121 |
| 4.4.2.5 In-vitro Drug Release Study .....                                                            | 121 |
| 4.4.2.6 FTIR .....                                                                                   | 123 |
| 4.4.2.7 Differential scanning calorimetry .....                                                      | 124 |
| 4.4.2.8 Molecular weight determination .....                                                         | 125 |
| 4.4.2.9 NMR Spectroscopy .....                                                                       | 126 |
| 4.4.2.10 Transmission electron microscopy .....                                                      | 127 |
| 4.4.3 PTX LOADED GLYCERYL TRISTEARATE SLN .....                                                      | 128 |
| 4.4.3.1 Partitioning of PTX between lipids and distilled water .....                                 | 128 |
| 4.4.3.2 Preparation of GTS SLN by solvent diffusion technique .....                                  | 129 |
| 4.4.3.3 Characterization of PTX loaded GTS SLN and coumarin-6 loaded GTS SLN<br>.....                | 133 |
| 4.4.3.4 Effect of different cryoprotectants added during freeze drying on stability<br>of NPs .....  | 133 |

|                                                                                      |     |
|--------------------------------------------------------------------------------------|-----|
| 4.4.3.5 In-vitro drug release study.....                                             | 134 |
| 4.4.3.6 Differential Scanning Calorimetry.....                                       | 135 |
| 4.4.3.7 X-ray diffraction patterns.....                                              | 136 |
| 4.4.3.8 Transmission electron microscopy .....                                       | 138 |
| 4.4.3.9 Determination of in vitro steric stability by electrolyte flocculation test. | 139 |
| 4.4.4 STABILITY STUDIES .....                                                        | 140 |
| 4.5 CONCLUSIONS .....                                                                | 147 |
| References .....                                                                     | 148 |
| 5. IN-VITRO CELL LINE STUDIES .....                                                  | 157 |
| 5.1 INTRODUCTION .....                                                               | 157 |
| 5.2 MATERIALS .....                                                                  | 157 |
| 5.3 METHODS .....                                                                    | 157 |
| 5.3.1 Cell Culture .....                                                             | 157 |
| 5.3.2 Fluorescent microscopy and Intracellular uptake of 6-coumarin .....            | 158 |
| 5.3.3 In-vitro cell cytotoxicity assay .....                                         | 159 |
| 5.4 RESULTS AND DISCUSSION .....                                                     | 159 |
| 5.4.1 Intracellular uptake efficiency.....                                           | 159 |
| 5.4.2 In-vitro cell cytotoxicity assay .....                                         | 165 |
| 5.5 CONCLUSIONS .....                                                                | 173 |
| References .....                                                                     | 173 |
| 6. IN-VIVO PHARMACOKINETIC AND BIODISTRIBUTION STUDIES .....                         | 175 |
| 6.1 INTRODUCTION .....                                                               | 175 |
| 6.2 ANIMALS .....                                                                    | 175 |
| 6.3 METHODS .....                                                                    | 175 |
| 6.3.1 Implantation of tumor cells.....                                               | 176 |
| 6.3.2 Pharmacokinetic and Biodistribution studies .....                              | 176 |
| 6.3.3 Statistical analysis .....                                                     | 176 |
| 6.4 RESULTS AND DISCUSSION .....                                                     | 177 |
| 6.4.1 Tumor formation.....                                                           | 177 |
| 6.4.2 Pharmacokinetics and Biodistribution .....                                     | 178 |
| 6.5 CONCLUSIONS .....                                                                | 188 |
| References .....                                                                     | 189 |
| 7. SUMMARY AND CONCLUSIONS .....                                                     | 191 |